Boston Children’s Hospital will serve as one of 24 test sites in the U.S. for a Phase 3 clinical trial of Santhera Pharmaceuticals’ experimental drug for Duchenne muscular dystrophy, reports The Boston Globe.
Duchenne muscular dystrophy is a rare degenerative condition that causes muscle weakness, loss of movement and eventually death.
Santhera’s proposed treatment, Raxone, aims to treat the respiratory failure associated with the disease, according to the report.
Why pharmacists can’t speak up when they know customers are overpaying for drugs
Sanofi, Lonza to build $285M biologics facility
Pharma leaders, healthcare experts advocate value-based payments for drugs
Abbott Laboratories announced a plan to invest $500 million to expand its U.S. manufacturing footprint. The medical device maker will…
In the face of persistent disruptions across supply chains, health systems across the country are making strides to help strengthen…
President Donald Trump has threatened tariffs on pharmaceutical imports, with U.S. Commerce Secretary Howard Lutnick confirming that the tariffs will…
Comments are closed.
